43 filings
8-K
CGTX
Cognition Therapeutics, Inc.
13 Sep 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
8-K
CGTX
Cognition Therapeutics, Inc.
28 Aug 24
Regulation FD Disclosure
6:26am
8-K
CGTX
Cognition Therapeutics, Inc.
8 Aug 24
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
7:12am
8-K
CGTX
Cognition Therapeutics, Inc.
29 Jul 24
Other Events
8:30am
8-K
CGTX
Cognition Therapeutics, Inc.
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
pb00a1d6z4zzkoe
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
8-K
bc81eznapqznjg1
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
8-K
o8e0teuhmd3vc 4k7
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
8-K
pri2rpuo66kleny2
11 Mar 24
Results of Operations and Financial Condition
4:11pm
8-K
el62w xa1ke1fp
20 Feb 24
Departure of Directors or Certain Officers
4:44pm
8-K
xf7jua01yn mt7cn
4 Jan 24
Other Events
4:21pm
8-K
f1j0vhq2cgq6rp
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
j8dka5h mnrv5dr
12 Sep 23
Other Events
7:00am
8-K
l4hqmq
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
qkj9q1x8t2zcuf c6kll
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
ot6up fhv8yhk59cs
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
dt8zmj oycakrbp
12 Jun 23
Submission of Matters to a Vote of Security Holders
7:41am
8-K
uoo5qz9siu
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
zjqhgywk
1 May 23
Departure of Directors or Certain Officers
7:30am
8-K
e19 39exe
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am